Zobrazeno 1 - 10
of 36
pro vyhledávání: '"D C, Case"'
Publikováno v:
Blood. 82:3564-3573
An intensive chemotherapy regimen (EVDAC), including high-dose epirubicin, vincristine, and dexamethasone followed by cyclophosphamide and high-dose cytarabine, was administered to 54 untreated adults with intermediate or high-grade non-Hodgkin's lym
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66eb2e13482137725d03d3cd9fecd624
https://doi.org/10.1182/blood.v82.12.3564.bloodjournal82123564
https://doi.org/10.1182/blood.v82.12.3564.bloodjournal82123564
Autor:
P H, Wiernik, P L, Banks, D C, Case, Z A, Arlin, P O, Periman, M B, Todd, P S, Ritch, R E, Enck, A B, Weitberg
Publikováno v:
Blood. 79:313-319
The purpose of this study was to determine the relative merits of idarubicin and daunorubicin in acute myeloid leukemia (AML) therapy. Thirty-two sites provided 214 previously untreated adults with AML aged 15 years or more who were randomized to rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2402039eb256b91850545ae38e88d40
https://doi.org/10.1182/blood.v79.2.313.bloodjournal792313
https://doi.org/10.1182/blood.v79.2.313.bloodjournal792313
Autor:
J J Stuart, Harvey M. Golomb, R S Stein, S E Rivkin, R H Wheeler, Costanzi, B A Peterson, Richard T. Silver, T P Miller, D C Case
Publikováno v:
Journal of Clinical Oncology. 9:754-761
In this phase II multicenter trial, the efficacy and safety of mitoxantrone (Novantrone; Lederle Laboratories, Wayne, NJ) were evaluated in the treatment of 206 patients with relapsed non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) previously
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::167cd0b5d1a417102a1163db320b1acc
https://doi.org/10.1200/jco.1991.9.5.754
https://doi.org/10.1200/jco.1991.9.5.754
Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy
Autor:
D H, Henry, B J, Brooks, D C, Case, E, Fishkin, R, Jacobson, A M, Keller, J, Kugler, J, Moore, R T, Silver, A M, Storniolo, R I, Abels, D S, Gordon, R, Nelson, K, Larholt, E, Bryant, S, Rudnick
Publikováno v:
The cancer journal from Scientific American. 1(4)
To assess whether the administration of recombinant human erythropoietin (r-HuEPO) would increase the hematocrit, reduce the requirement for transfusion, and improve the quality of life in anemic cancer patients receiving myelosuppressive, cisplatin-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::223281b601d4fd6443e84d5bdc9ea6b5
https://pubmed.ncbi.nlm.nih.gov/9166482
https://pubmed.ncbi.nlm.nih.gov/9166482
Autor:
B R, Greenberg, R D, Reynolds, C B, Charron, K M, Squillace, L S, Lessin, D C, Case, R A, Gams
Publikováno v:
Cancer. 71(6)
Idarubicin, a new anthracycline analogue, is available in an oral preparation, and responses have been observed using relatively aggressive therapy in patients with myelodysplastic syndromes (MDS). The authors studied whether a chronic low-dose sched
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3b1a305afae9a11c1428c57c9760d473
https://pubmed.ncbi.nlm.nih.gov/8443750
https://pubmed.ncbi.nlm.nih.gov/8443750
Publikováno v:
Cancer investigation. 10(1)
To study the efficiency of high-dose melphalan in previously untreated patients with advanced myeloma, we performed a Phase I-II trial. Twenty-eight patients were treated at dose level of 60-140 mg/m2. Each patient was first treated with a priming do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::df217d890e6663fdbec8d281dda7fd9d
https://pubmed.ncbi.nlm.nih.gov/1735010
https://pubmed.ncbi.nlm.nih.gov/1735010
Publikováno v:
Cancer research. 50(21)
Idarubicin, a new analogue of daunorubicin, was administered p.o. for 3 consecutive days every 3 weeks at a dose of 45 mg/m2 in 46 patients (45 eligible and evaluable) with previously treated, favorable histology, non-Hodgkin's lymphoma. Median clini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6cba545971bdd1eb7ffc2937377e0cd1
https://pubmed.ncbi.nlm.nih.gov/2208149
https://pubmed.ncbi.nlm.nih.gov/2208149
Autor:
Z, Arlin, D C, Case, J, Moore, P, Wiernik, E, Feldman, S, Saletan, P, Desai, L, Sia, K, Cartwright
Publikováno v:
Leukemia. 4(3)
This phase III, randomized trial in previously untreated adults with ANLL compared mitoxantrone plus cytosine arabinoside with the CALGB "7 + 3" daunorubicin-based regimen. Two hundred evaluable patients (98 treated with the mitoxantrone-based regime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fd334019f4de70142862d295aeb58332
https://pubmed.ncbi.nlm.nih.gov/2179638
https://pubmed.ncbi.nlm.nih.gov/2179638
Autor:
M R, Cooper, A, Fefer, J, Thompson, D C, Case, R, Kempf, R, Sacher, J, Neefe, J, Bickers, J H, Scarffe, R, Spiegel
Publikováno v:
Cancer treatment reports. 70(4)
Alpha-2-interferon (IFN) has demonstrable activity in advanced, relapsing, or refractory multiple myeloma. Because of the in vitro synergism between the IFNs and cytotoxic agents, we conducted a trial of 30 previously untreated patients with multiple
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d70a9125eebcfc9237967e432cbc94bf
https://pubmed.ncbi.nlm.nih.gov/3698041
https://pubmed.ncbi.nlm.nih.gov/3698041
Autor:
D C, Case
Publikováno v:
The Journal of the Maine Medical Association. 68(9)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::293412ed64c7ffd1d9ddcc365049eaad
https://pubmed.ncbi.nlm.nih.gov/925510
https://pubmed.ncbi.nlm.nih.gov/925510